InnovationRx: Antitrust Regulators OK Oracle-Cerner Deal; Plus, Covid Vaccine Mixing And Matching – Forbes


InnovationRx is your weekly digest of healthcare news. To get it in your inbox, subscribe here.
Antitrust regulators, including the European Commission, have greenlit Oracle’s acquisition of healthcare technology company Cerner, the company said Wednesday afternoon. Oracle first announced its plans to buy Cerner for $28.3 billion with an all cash tender offer of $95 a share in December 2021, as the database and cloud infrastructure company looks to expand its footprint in the healthcare sector. Cerner shares closed at $94.69 on Wednesday and were slightly up by 0.25% in after hours trading.
Kansas City, Missouri-based Cerner, which is best known for its electronic medical records software, holds around 25% of the U.S. hospital market share, second only to privately held Verona, Wisconsin-based Epic Systems, according to KLAS Research. “Healthcare is the largest and most important vertical market in the world—$3.8 trillion last year in the United States alone. Oracle’s revenue growth rate has already been increasing this year—Cerner will be a huge additional revenue growth engine for years to come as we expand its business into many more countries throughout the world,” Oracle CEO Safra Catz said in a statement. Cerner reported nearly $5.8 billion in revenue in 2021, up 5% compared to the same period in 2020.

Experts are unsure how long monkeypox has been spreading outside the regions of Africa it is usually found.
Bavarian Nordic, a Danish biotech that manufactures the only authorized vaccine against monkeypox in the world, has been “bombarded” with acquisition requests—including from countries that have not reported monkeypox cases, spokesman Rolf Sass Sørensen told Forbes. Other companies that produce vaccines and treatments for smallpox that could be deployed to tackle monkeypox include Emergent BioSolutions and Siga Technologies. Covid-19 vaccine manufacturer Moderna says it’s in the early stages of “investigating potential monkeypox vaccines.” Read more here.

The $100 Genome: Ultima Genomics emerged from stealth this week with $600 million in funding and claims of technology that can sequence an entire genome for $100. The first human genome cost around $1 billion and the current cost is less than $1,000. Ultima, which has backing from investors including General Atlantic, Andreessen Horowitz and Khosla Ventures, plans to present scientific results at the Advances in Genome Biology and Technology conference next week .
Direct Primary Care: Hint Health, a startup that offers management and billing software to doctors so they can open membership-based primary care practices, has raised a $45 million Series B funding round led by Banneker Partners and Frist Cressey Ventures.
Partnership For Expanding Rural Care: Homeward, the company founded by former Livongo team members with an aim to improve access to health in rural communities, announced this week that it’s partnering with Rite-Aid to provide medical services for seniors.
Rite Aid’s leadership team is highlighting the drugstore chain’s growing pharmacy benefit management company and other assets amid buyout rumblings.
The federal “No Surprises Act” prevented 2 million surprise medical bills in 2 months, according to health insurance industry study.
The Ireland-based startup Luminate, which is developing a product to prevent hair loss during chemotherapy, has raised $5 million.
New study finds the U.S. spends twice as much on cancer care than average for high-income countries but mortality rates are only slightly better than average for these countries.
A new analysis published this week answered a question about mRNA vaccines that many people had: namely, would there be an advantage to “mixing and matching” the Pfizer and Moderna vaccines, or is it better to have all the same doses be the same vaccine? After analyzing the results of over 50 studies, a group of researchers determined that it really doesn’t matter. The most important benefit, they determined, comes from getting a booster shot. An mRNA booster shot, they found, helps prevent infections from the different Covid variants. Although there was one bit of evidence for mix-and-matching: people who got two adenovirus vaccines, then a mRNA booster, saw less infections.
A dog being trained to identify Covid.
Dogs were more effective at detecting positive cases of Covid-19 through human sweat samples than nasal antigen tests, a new study suggests. The findings may help develop better ways to diagnose the disease. Read more here.





Shares in China companies traded on the Nasdaq and New York Stock Exchange notched up big gains as Shanghai partly eased lockdowns tied to stringent Covid policies.
People experiencing a rebound Covid-19 infection after taking the antiviral therapy medication Paxlovid can be contagious even before experiencing symptoms, according to new research that has prompted the CDC to issue new guidance on the drug.
Nearly 1,000 flights were canceled over Memorial Day weekend, thanks to a combination of bad weather conditions and Covid-19 infections causing staff shortages.
New studies suggest that Covid can lead to prolonged gastrointestinal infections, even after respiratory symptoms stop.
‘Top Gun: Maverick’ Puts Tom Cruise On Track To Best Will Smith’s Record Hollywood Payday
From Bombs To Birth: A Pregnant Mom’s Journey From War-Torn Ukraine
How To Become A Billionaire At 87
During the Omicron Wave, Death Rates Soared for Older People (New York Times)
Monkeypox Outbreaks: 4 Key Questions Scientists Have (Scientific American)
States Are Housing High-Needs Foster Kids in Offices and Hotels (Kaiser Health News)

source


Leave a Reply

Your email address will not be published.